Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
Papillomavirus Infections
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 314 (final count)
- Started
- May 17, 2021
- Main results expected
- Apr 6, 2024
- Fully finished
- Apr 6, 2024
- Results posted
- May 30, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Measured over: 1 month after final dose (Month 7)
Number of Participants With at Least 1 Injection-site Adverse Event (AE)
Measured over: Up to 5 days after each vaccination (up to ~6 months)
Number of Participants With at Least 1 Systemic Adverse Event
Measured over: Up to 15 days after each vaccination (up to ~6.5 months)
Number of Participants With at Least 1 Serious Adverse Event (SAE)
Measured over: Up to ~Month 30
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04772534 · record last updated 2025-05-30 · checked 2026-11-09 15:47 UTC